Relay Pharma - RLAY Quarterly EPS earnings growth

Corporate company logo of Relay Therapeutics, Inc. (RLAY)

Relay Therapeutics' experienced management leverages advanced AI technologies to develop precision oncology drugs. This chart on GURU.Markets displays the quarterly growth of net income per share, where the 13.40 mark indicates the current trend level. The asset's value growth is supported by the success of RLY-2608 trials and a significant capital reserve for further development.

relaytx.com (RLAY) Year-over-year earnings per one share growth for the last 12 months: for the period 07/04/2022 - 11/12/2026

Analytical breakdowns for Relay Therapeutics

- share price and consensus valuation forecast:
Stock Quotes Relay Therapeutics, Inc.|RLAY - Analyst Forecast Prices
- issuer market value details:
Market Capitalization Relay Pharma|RLAY - Enterprise Value
- balance sheet net asset value indicators:
Net Assets per Single Share Relay Therapeutics|RLAY - Accounting Value of Company|Market Capitalization to Book Value Ratio relaytx.com|RLAY - Company Balance Sheet Assets
- debt and liquidity data:
Total Debt to Capital Relay Therapeutics|RLAY - Long-Term Liabilities to Capital|Short-Term Debt to Equity Ratio Relay Therapeutics|RLAY - Company Cumulative Indebtedness|Debts to Book Capitalization Relay Pharma|RLAY - Long-Term Debt|Company Short-Term Debts Relay Therapeutics|Quick Liquidity Indicator relaytx.com
- earnings and market multiples details:
RLAY - Final Profit|Future Profit Relay Therapeutics|RLAY - Market Price to Net Income Ratio|Forward P/E Multiple Relay Pharma|RLAY - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple Relay Pharma|RLAY - Profit before interest, taxes and amortization|Earnings per share for the last twelve months Relay Therapeutics|RLAY - Earnings per share for the trailing year|Quarterly EPS earnings growth relaytx.com|RLAY - Earnings growth in current year|Net earnings per share growth forecast for next year Relay Therapeutics
Fundamental company valuation:Relay Therapeutics, Inc. - RLAY
Flagship merchandise of relaytx.com

This indicator measures the dynamics of net earnings per share compared to the same period last year. By analyzing the quarterly shift in earnings per share, an investor determines the business scaling rate and the risk of asset overvaluation. For Relay Therapeutics (RLAY), this metric reflects the cost efficiency of energy-intensive supercomputers used in drug modeling. The stability of this metric confirms the resilience of the operating model, while sharp fluctuations signal a shift in market expectations.

Analysis of competing companies

GMAB (Genmab) - Year-over-year net earnings per share growth for the last 12 months|EXEL: Year-over-year earnings per share growth rate for the last twelve months|NUVL (Nuvalent Corp) - Quarterly EPS earnings growth|Quarterly EPS earnings growth Kymera Corp|Year-over-year earnings per share growth for the last twelve months IDEAYA Biosciences (IDYA)|ELVN (enliventherapeutics.com) - Year-over-year earnings per one share growth for the last 12 months|Quarterly EPS earnings growth ORIC (ORIC Pharmaceuticals, Inc.)|Net earnings per share growth for the trailing year Nurix Therapeutics Inc|Tyra Bio - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Verastem Corp|GLUE (Monte Rosa Therapeutics) - Year-over-year net earnings per share growth for the last 12 months|CGEM: Year-over-year earnings per share growth rate for the last twelve months|IMRX (Immuneering) - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months C4 Therapeutics Inc CCCC|Quarterly EPS earnings growth BDTX|Repare Therapeutics Inc - Year-over-year earnings per share growth for the last 12 months|PMV Pharmaceuticals - Year-over-year net earnings per share growth for the last 12 months|Year-over-year earnings per one share growth for the last 12 months KPTI|PPCB: Year-over-year net earnings per share growth for the last 12 months|Bio Green Med Solution Inc. - Year-over-year earnings per share growth rate for the last twelve months|AADI: Quarterly EPS earnings growth|Aileron Therapeutics, Inc. - Year-over-year earnings per one share growth for the last 12 months|BPMC (Blueprint Medicines Corp.) - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months GlycoMimetics Corp GLYC|Year-over-year earnings per share growth for the last twelve months SpringWorks Therapeutics, Inc. (SWTX)